Navigation Links
Groundbreaking clinical trial looks at fecal transplant as treatment for C. difficile
Date:8/21/2012

(PROVIDENCE, R.I.) For patients with Clostridium difficile (C. difficile), a persistent and potentially deadly bacterial illness, severe diarrhea, abdominal pain, nausea and vomiting are an everyday event. This particularly virulent infection is prone to recurrence, even after multiple courses of expensive antibiotics, and treatment options are limited for patients who continually relapse or develop antibiotic resistance.

Now, a new National Institutes of Health research grant awarded to Colleen Kelly, M.D., a gastroenterologist with the Center for Women's Gastrointestinal Medicine at the Women's Medicine Collaborative, and co-investigator Lawrence Brandt, M.D., from the Albert Einstein School of Medicine in New York, will test whether an unconventional yet promising treatment known as fecal bacteriotherapy, or fecal transplantation, is an effective therapy for patients with relapsing C. difficile.

While it sounds unpleasant, previous research suggests fecal transplantation, which involves transplanting healthy donor stool into the patient's colon during a colonoscopy, is extremely successful; according to published case studies, the procedure has "cured" relapsing C. difficile in 89 percent of patients without any complications. However, few physicians know about the procedure, which has been around for more than 50 years, and to date there have been no published prospective clinical trials of fecal transplant for C. difficile.

Kelly's research will be the first randomized controlled clinical trial of this procedure as a treatment for relapsing C. difficile.

"Our goal is to clearly demonstrate to both the medical community and health insurers that fecal transplant is an viable, safe, inexpensive, and ultimately curative treatment for patients with relapsing C. difficile," said Kelly. "We hope this research is the first step toward developing standard treatment protocols for this procedure and making it more widely available to the many patients who are suffering from recurring C. difficle."

C. difficile affects tens of thousands of Americans each year, particularly patients in hospitals or long-term care facilities, and typically occurs after a dose of antibiotic medications. It has been increasing in both incidence and severity over the last decade, including otherwise healthy people who aren't hospitalized or taking antibiotics. It causes 14,000 deaths annually, according to the Centers for Disease Control and Prevention.

C. difficile disrupts the balance of the normal, healthy, protective bacterial flora found in the colon. When that happens often following a dose of antibiotics invasive bacteria like C. difficile can grow, proliferate and produce toxins that make patients sick.

Approximately 20 percent of patients have recurring C. difficile that does not respond to antibiotics. Patients who experience one recurrence have a 40 percent risk of further relapse, while those with two or more episodes face a 60 percent relapse risk. While the first relapse is generally treated with a second course of antibiotics, current guidelines recommend a tapering course of an expensive antibiotic known as oral vancomycin following a second recurrence.

During a fecal transplant, healthy donor stool is mixed with saline and infused into the colon during a standard outpatient colonoscopy procedure. The patient identifies the donor usually a family member or close friend ahead of time, and the donor undergoes a rigorous screening process. A stool sample is obtained the morning of the procedure.

Kelly, who is also a clinical assistant professor of medicine at The Warren Alpert Medical School of Brown University, says fecal transplant works because the donor stool contains the healthy bacteria needed to restore and repopulate the patient's colon with what she calls an "army of good bacteria" to keep C. difficle from overgrowing and causing disease.

Kelly and Brandt hope to enroll 48 patients in this randomized study, which will determine if fecal transplantation, using stool from a healthy volunteer donor, provides a cure for relapsing C. difficile infection. Collaborating investigators at the University of Minnesota will analyze the complex bacterial communities in stool collected from patients both before and after transplant, as well as their donors.

"Given the increasing incidence and severity of C. difficile infection, the problem of recurrent disease in a significant number of patients, and the economic burden and drug-resistant infections associated with long term use of oral antibiotics, we need this clinical trial to determine whether fecal transplant is an effective treatment for relapsing infection," said Kelly.


'/>"/>
Contact: Jessica Collins Grimes
jgrimes2@lifespan.org
401-793-7484
Lifespan
Source:Eurekalert

Related medicine news :

1. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
2. IU researchers interview pro-anorexic bloggers for groundbreaking new study
3. Groundbreaking Nigeria summit results in major commitment to reduce child deaths
4. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
5. New method may allow personalized clinical trial for cancer therapies
6. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
7. NYU School of Medicine announces new clinical trial for ulcerative colitis
8. Published clinical trial demonstrates efficacy of Sea-Band for migraine-related nausea
9. Clinical trial seeks to cure advanced Crohns disease using bone marrow transplant
10. 32-country study shows that type 2 diabetes drug is clinically effective for long-term use
11. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... VEGAS , June 26, 2016 ... to value-based care operating models within the health care ... enable greater financial efficiency , Deloitte offers a ... the key business issues impacting efficient cost optimization: labor ... , These services facilitate better outcomes and better ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology: